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Epoxyeicosatrienoic Acids Regulate Adipocyte
Differentiation of Mouse 3T3 Cells, Via PGC-1a Activation,
Which Is Required for HO-1 Expression and Increased
Mitochondrial Function
Maayan Waldman,1,2,* Lars Bellner,1,* Luca Vanella,1,3,* Joseph Schragenheim,1 Komal Sodhi,4
Shailendra P. Singh,1 Daohong Lin,1 Anand Lakhkar,1 Jiangwei Li,5 Edith Hochhauser,2 Michael Arad,6
Zbigniew Darzynkiewicz,5 Attallah Kappas,7 and Nader G. Abraham1,4,7,8
Epoxyeicosatrienoic acid (EET) contributes to browning of white adipose stem cells to ameliorate obesity/
diabetes and insulin resistance. In the current study, we show that EET altered preadipocyte function, enhanced
peroxisome proliferation-activated receptor g coactivator a (PGC-1a) expression, and increased mitochondrial
function in the 3T3-L1 preadipocyte subjected to adipogenesis. Cells treated with EET resulted in an increase,
P < 0.05, in PGC-1a and a decrease in mitochondria-derived ROS (MitoSox), P < 0.05. The EET increase in
heme oxygenase-1 (HO-1) levels is dependent on activation of PGC-1a as cells deficient in PGC-1a (PGC-1a
knockout adipocyte cell) have an impaired ability to express HO-1, P< 0.02. Additionally, adipocytes treated
with EET exhibited an increase in mitochondrial superoxide dismutase (SOD) in a PGC-1a-dependent manner,
P < 0.05. The increase in PGC-1a was associated with an increase in b-catenin, P< 0.05, adiponectin expres-
sion, P < 0.05, and lipid accumulation, P< 0.02. EET decreased heme levels and mitochondria-derived ROS
(MitoSox), P< 0.05, compared to adipocytes that were untreated. EET also decreased mesoderm-specific
transcript (MEST) mRNA and protein levels (P < 0.05). Adipocyte secretion of EET act in an autocrine/
paracrine manner to increase PGC-1a is required for activation of HO-1 expression. This is the first study to
dissect the mechanism by which the antiadipogenic and anti-inflammatory lipid, EET, induces the PGC-1a
signaling cascade and reprograms the adipocyte phenotype by regulating mitochondrial function and HO-1
expression, leading to an increase in healthy, that is, small, adipocytes and a decrease in adipocyte enlargement
and terminal differentiation. This is manifested by an increase in mitochondrial function and an increase in the
canonical Wnt signaling cascade during adipocyte proliferation and terminal differentiation.
Introduction
The cytochromeP450 (CYP)monooxygenase/epoxygenasefamily is responsible for formation of 20-hydroxyeico-
satetraenoic acid (20-HETE) and epoxyeicosatrienoic acids
(EETs) [1,2]. Upon formation, EETs are rapidly hydrolyzed
by soluble epoxide hydrolases (sEHs) and reactive oxygen
species (ROS) [heme oxygenase-1 (preventable by HO-1)
induction] to their respective dihydroxyepoxytrienoic acids
(DHETs), as well as to esterification primarily to glycero-
phospholipids. Vasodilatory, anti-inflammatory, and antiapop-
totic actions of EETs are well established, and sEH inhibition
significantly increases cellular and circulating EET levels [3,4].
EET increases osteoblast differentiation but decreases adipocyte
differentiation via activation of HO-1 (HO-1) [5–7]. In 3T3
adipocyte cells, an increase in heme increases adipogenesis
[8,9], which is associated with a glucose-mediated increase
in ROS, which inactivates HO-1 (reviewed [10]).
The 3T3 adipocyte is a model to study the role of PGC-1
as thermogenic activators, the mitochondrial heme path-
way, and biogenesis [11] as well as the evaluation of heme
homeostasis [12]. However, an increase in HO-1 gene
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expression decreases adipocyte heme and subsequently
attenuates (hypertrophy) adipogenesis [10]. This reduction
in adipogenesis is associated with an increase in the levels
of EETs [13], which increase hematopoietic stem cell
transplant engraftment that is associated with activation of
the transcriptional factor activator protein 1 (AP-1) [14].
The AP-1 binding site is present in the human HO-1 pro-
moter that activates HO-1 gene expression [15]. Therefore,
the mechanism by which EET increases HO-1 expression
may not be related solely to inhibition by the BTB and CNC
homology 1, basic leucine zipper transcription factor 1 (Bach
1) [16]. EET affects adipocyte differentiation and hypertro-
phy both in vitro and in vivo [7,17,18] by reprogramming the
adipocyte phenotype.
The development of adipocytes in mice and humans
follows a clearly defined pathway (adipogenesis) that begins
with a common mesenchymal stem cell (MSC) that is plu-
ripotent [19]. The early steps of the pathway leading to the
generation and the commitment of MSCs to adipocyte lin-
eage are unknown. Hypothetically, the determination of the
fate of MSCs occurs early in the stages of cell differentia-
tion (‘‘commitment’’) and involves the interplay of intrinsic
(genetic) and environmental (local and systemic) conditions
to ultimately define cell fate. Factors such as those discussed
earlier, that determine MSC proliferation and differentia-
tion, also govern early adipocyte development and function.
Currently, little is known about this process—from MSC to
preadipocytes to adipocyte differentiation.
During adipogenesis, MSCs or preadipocytes differentiate
into lipid-laden and insulin-sensitive adipocytes [20]. The
acquisition of adipocyte phenotype and development of adi-
pocyte function is characterized by chronological changes in
the expression of multiple genes. Briefly, the stages of adi-
pocyte differentiation are as follows: (1) MSC-derived adi-
pocyte growth arrest, (2) clonal expansion, (3) a second stage
of growth arrest or early differentiation, and (4) terminal
differentiation—development of a mature adipocyte pheno-
type [21,22]. Concurrently as cells proceed to differentiation,
there is an increase in transcription or de novo expression of
several genes, including adiponectin, Glut 4, insulin receptor,
and fatty acid synthase [21]. In the early phase of differen-
tiation, preadipocyte cells are morphologically similar to fi-
broblasts. After clonal expansion, continued induction of
adipogenesis leads to a drastic change in cell shape. Pre-
adipocytes convert to a spherical shape; lipid droplets accu-
mulate, and the preadipocyte progressively acquires the
morphological and biochemical characteristics of a mature
adipocyte, followed by triglyceride accumulation [22].
Administration of EET or inhibitors of sEH to obese mice
is associated with a decrease in visceral subcutaneous fat and
an increase in insulin sensitivity [23–26]. The CYP2J2-
mediated increase in EET increases fatty acid oxidation and
adiposity [17,27,28]. Although EETs exhibit potent biologi-
cal effects, including vasodilatation and inhibition of the in-
flammatory response [4,29,30] and in adiposity [17,27,28],
their influence on mitochondrial function and proliferator-
activated receptor gamma coactivator-1a (PGC-1a) in rela-
tion to adipogenesis remains unknown.
Peroxisome PGC-1a was originally described as a coac-
tivator of peroxisome proliferator-activated receptor-gamma
(PPAR-g) that modulates expression of uncoupling protein 1
(UCP-1) and thermogenesis in brown fat [31,32]. PGC-1a
controls mitochondrial biogenesis and oxidative metabolism
in many tissues, including brown adipose tissue [11,33].
Transgenic mice with mildly elevated muscle PGC-1a are
resistant to age-related obesity and diabetes resulting in a
prolongation of their life span, suggesting that PGC-1a in-
fluences the secretion of factors of biological influence that
affect the function of other tissues [34]. Adipose-specific
PGC-1a deficiency results in a decrease in mitochondrial
biogenesis and an increase in fatty acid oxidation, glucose,
and insulin resistance [35].
In the present study, we examined whether the EET-
mediated regulation of adiposity is due to activation of
PGC-1a and an increase in UCP-1, HO-1, and b-catenin,
resulting in decreased adipocyte terminal differentiation
through the regulation of heme levels, essential for adipo-
cyte proliferation and differentiation.
Materials and Methods
Cell culture
3T3-L1 mouse preadipocytes were purchased from the
ATCC (ATCC, Manassas, VA). After thawing, 3T3-L1
cells were resuspended in an a-minimal essential medium
(a-MEM; Invitrogen, Carlsbad, CA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS; Invitrogen) and
1% antibiotic/antimycotic solution (Invitrogen). The cul-
tures were maintained at 37C in a 5% CO2 incubator, and
the medium was changed after 48 h and every 3–4 days
thereafter. When the 3T3-L1 cells were confluent, the cells
were recovered by the addition of 0.25% trypsin/EDTA
(Invitrogen) and subcultured. For experiments, 3T3-L1 cells
were seeded in 96- and 24-well plates at a density of 10,000
cells/cm2 and cultured in a-MEM with 10% FBS until 90%
confluence was achieved. The medium was then replaced
with adipogenic medium, and the cells were cultured for
an additional 7 days. The adipogenic medium consisted of
Dulbecco’s modified Eagle’s medium (DMEM) with high
glucose (Invitrogen) supplemented with 10% (v/v) FBS,
10mg/mL insulin (Sigma-Aldrich, St. Louis, MO), 0.5mM
dexamethasone (Sigma-Aldrich), and 0.1mM indomethacin
(Sigma-Aldrich). For some experiments, cells were treated
with CoPP (Cobalt protoporphyrin; Frontier Scientific, Lo-
gan, UT) at a final concentration of 2–5mM, as indicated in
the figure legends; for 5–7 days, the EET analog, EET-A
[(S)-2-(11-(nonyloxy) undec-8(Z)-enamido) succinic acid],
was treated at a final dose of 1–10 mM, as indicated in the
figure legends. To examine the effect of inhibition of HO
activity on EET-A-treated cell, SnMP (2 mM, Tin meso-
porphyrin; Frontier Scientific) was added for the duration of
EET-A treatment. Cells and conditioned media were col-
lected after 7 days, as indicated in the figure legends.
At the experimental endpoints, cells were collected by
trypsinization, washed once with PBS, and then lysed for
both protein measurement and RNA extraction.
Isolation and development of PGC-1a-deficient
adipocytes
SMART vector lentiviral shRNA-PPARGC1A or scram-
bledRNA(Dharmacon, Lafayette, CO)was applied to 3T3-L1
cells to establish a stably transduced cell line. Briefly, 1· 106
cells were seeded in six-well plates 1 day before transduction.
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On the day of transduction, the transduction medium was
made by 1· 106 transducing units of lentiviral particles with
0.5mL a-MEM growth medium applied to each well and in-
cubated for 3 h to maximize the contact between each cell and
lentiviral particles. Cells were also treated with the transduc-
tion medium without lentiviral particles, which served as un-
transduced control. Growth medium (1.5mL) was then added
to each well in the presence of 8mg/mL polybrene (final
concentration). After 48-h incubation, antibiotic selection
medium (a-MEMgrowthmediumwith 10mg/mL puromycin)
was used to kill all the untransduced cells for either lenti-
scramble or cells treated with lentiviral shRNA-PPARGC1A.
The growth medium was replaced every 2 days and used for
differentiation and experimental studies.
Oil Red O staining
0.21% Oil Red O in 100% isopropanol (Sigma-Aldrich)
was used for staining, as previously described [18]. Briefly,
adipocytes were fixed in 10% formaldehyde, stained with Oil
Red O for 10min, and rinsed with 60% isopropanol (Sigma-
Aldrich), where after the Oil Red O was eluted by incubation
in 100ml 100% isopropanol for 10min and then the OD read
at 490 nm for 0.5 s, as previously described [7,18].
Lipid droplet size analysis. The lipid droplet size and
number were acquired by analyzing the whole bottom surface
area of an individual well of a 96-well plate. Each experiment
was performed in triplicate, and the droplet analysis was
performed [G]. The photographs are representative images of
the experimental conditions. Cell size was measured using an
ImagePro Analyzer (MediaCybernetics, Inc., Rockville,
MD). The classification of the size of lipid droplets was based
on the size of the two-dimensional area and expressed as
pixels as we previously described [6].
Flow cytometer measurement of MitoSox
Mitochondrial superoxide formation was determined by
the uptake of MitoSox Red reagent (Invitrogen) in live
cells, as previously described [36]. Briefly, cells were plated
at a density of 10,000 cells/cm2 in six-well plates, with or
without EET-A, 10 mM, overnight and then incubated with
Hoechst nuclear stain (5mg/mL) for 30min in complete me-
dium. The medium was removed, and the cells were incu-
bated with MitoSox Red reagent (5 mM) in Hank’s balanced
salt solution for 10min at 37C protected from light. The cells
were then washed twice with PBS, collected by trypsiniza-
tion, and finally washed with PBS supplemented with 2%
bovine serum albumin (BSA; Fisher Scientific, Pittsburg,
PA). The cells were then fixed in 2% formaldehyde solution
for 10min, collected by centrifugation, and resuspended in
PBS supplemented with 2% BSA. Intensity of cellular fluo-
rescence was measured using a Beckman Coulter’s MoFlo
XDP flow cytometer (Beckman Coulter, Indianapolis, IA)
and analyzed with Kaluza v1.3 software (Beckman Coulter).
More than 16,000 cells were measured per sample. Data are
presented as a frequency distribution graph of fluorescence
intensity of individual cells plotted on a logarithmic coordi-
nate; the mean and SD are shown per individual sample. The
mean values from triplicate cultures were used to calculate
statistical difference between the control and EET-A-treated
cultures.
HPLC measurement of mitochondria-derived
ROS and heme measurement
Mitochondrial superoxide formation was determined by
the uptake of MitoSox Red reagent (Invitrogen) in live cells,
as previously described [37,38]. Briefly, cells were plated at
a density of 10,000 cells/cm2 in six-well plates with or
without EET-A, 10 mM, overnight and then incubated with
the MitoSox Red reagent (5mM) in Hank’s balanced salt
solution for 10min at 37C protected from light. The cells
were washed twice with PBS, and 300mL acetonitrile was
then added per well, followed by incubation on ice for 5min
protected from light. Cells were collected by scraping, and
the lysate was transferred into microcentrifuge tubes. Sam-
ples were incubated at -20C for 1 h, then pelleted by
centrifugation at 14,000g for 10min, and used for protein
measurement, and the supernatant was then collected and
stored at -25C until analyzed for MitoSox fluorescence
(excitation/emission 510/580) using an HPLC system with a
Jasco FP-1520 fluorescence detector and a Beckman ultra-
sphere reverse column (C18) (5m, 250 · 4.6mm), and the
values obtained were normalized to protein levels. Free
heme and degraded heme protein, including myoglobin,
were measured using a BioVision ELISA Kit (BioVision,
Inc., Milpitas, CA).
Cytokine measurements
Adiponectin (high molecular weight, HMW), interleukin
6 (IL-6), and IL-1a were determined in conditioned medium
using an ELISA Assay ELISA Kit (R&D Systems, Inc.,
Minneapolis, MN) according to the manufacturer’s in-
structions and as previously described [7,39].
Immunoblotting of signaling proteins
Cells were trypsinized, pelleted by centrifugation, and
lysed with lysis buffer supplemented with protease and
phosphatase inhibitors (complete Mini and PhosSTOP;
Roche Diagnostics, Indianapolis, IA). Protein levels were
quantified using a commercial assay (Bio-Rad, Hercules,
CA). Protein samples were applied to sodium dodecyl sul-
fate (SDS) polyacrylamide gel (10%–15%), electrophoresed
under denaturing conditions, and electrotransferred onto
PVDF Immobilon-P membrane (Amersham Pharmacia,
Piscataway, NJ) using a semidry transfer apparatus (Bio-
Rad). Membranes were blocked with Odyssey Blocking
Buffer (TBS) (LI-COR, Lincoln, NE) for 1 h at room
temperature. Primary antibodies (1:500–1:1,000 dilution)
in blocking buffer supplemented with 0.1% Tween 20
(Fisher Scientific) were incubated overnight at 4C,
washed in Tris-buffered saline (TBS) supplemented with
0.1% Tween 20, and then incubated with the appropriate
fluorophore-conjugated secondary antibodies (1:5,000–
1;20,000) (LI-COR). Detection was completed with a LI-COR
Odyssey instrument (LI-COR), and quantification of signals
was completed with the Odyssey program (LI-COR).
Quantitative real-time PCR
Briefly, total RNA was extracted from pelleted cells using
TRIzol (Ambion, Austin, TX) according to themanufacturer’s
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instructions. Concentration of total RNA was determined by
the use of a Take3 plate and a Biotek Plate Reader (Biotek,
Winooski, VT). cDNA was synthesized from 1mg total RNA
and 18s using the High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA) according to
themanufacturer’s protocol, and PCRmRNA calculationwas
adjusted to 18s as control. Quantitative real-time PCR anal-
ysis was performed using the 7500 Fast Real-Time PCR
System (Applied Biosystems). The gene expression analysis
levels were determined using the relative expression method
with the threshold crossing point (Ct-value) as basis and as
described [40].
Statistical analysis
The treatment groups were compared with the control
group, and the experiments were analyzed using one-way
analyses of variance (ANOVA) with Bonferroni tests for
multiple comparisons. Data are presented as mean–SE. Sta-
tistical significance was defined as P< 0.05.
Results
EET reduces adipogenesis in differentiated
adipocytes
We examined the effect of CoPP on HO-1 induction and
EET-A on adipocyte function by measuring the total amount
of lipids. Differentiated adipocyte cells treated with either
EET-A or CoPP display reduced large lipid droplet content
compared with differentiated control cells (P< 0.05), an
effect that was completely prevented by concomitant treat-
ment with EET-A and an inhibitor of HO activity, SnMP
(Fig. 1A). The results are quantitated in Fig. 1B. The effect
of EET-A on adipogenesis was determined by counting cells
with small lipid droplets in the cytoplasm and compared
with large adipocytes (Fig. 1B). The percentage of cells with
small lipid droplets increased in cells treated with EET. In
differentiated cells treated with either EET or EET-SnMP
and compared with untreated cells, the percentage of small
and large lipid droplets is displayed in Fig. 1B, left and right
panels, respectively. EET-A decreased adipocyte terminal
FIG. 1. EET-AandCoPP increase
small adipocyte number and inhibit
adipocyte terminal differentiation.
3T3-L1 cells cultured in differenti-
ation medium were stained with Oil
RedO. (A)Representative images of
differentiated control cells and cells
treated with EET-A (1mM), EET-A
(1mM)+SnMP (5mM), and CoPP
(2mM).Analysis of lipid droplet size
(B). *P< 0.05 versus control. (C)
Representative blot and densitome-
try analysis ofPGC-1a protein levels
in the presence of EET (1mM) with
or without the addition of SnMP
(5mM). *P< 0.05 versus control,
n= 3. (D) PGC-1a mRNA levels in
the presence of EET-A (10mM)
with or without the addition of
SnMP (5mM). *P<0.05 versus con-
trol, n=3. EET-A, epoxyeicosatrienoic
acid; PGC-1a, proliferation-activated
receptor g coactivator a.
EET UPSTREAM OF PGC-1a REGULATES ADIPOCYTE DEVELOPMENT 1087
differentiation, that is, prevented the conversion of small
adipocytes to large adipocytes (Fig. 1B). The adipocyte cell
size in the absence of the EET-A agonist was 180– 3 pixels
compared with 100– 2.1 pixels in the presence of EET-A
(Fig. 1B, right panel).
We examined the levels of PGC-1a in adipocytes treated
with EET-A or SnMP. As seen in Fig. 1C, EET-A increased
PGC-1a levels, while SnMP largely prevented this effect.
These results were confirmed by the levels of PGC-1a
mRNA levels (Fig. 1D).
EET decreases inflammation during differentiation
of adipocytes
Treatment with EET-A reduced the levels of both IL-1a
and IL-6 compared with control, and SnMP blocked this
effect (Fig. 2A, B). Adiponectin levels in the conditioned
medium of adipocytes treated with EET-A were higher
(P < 0.05) compared with untreated adipocytes. SnMP
blocked the effect of EET-A (P< 0.05) (Fig. 2C).
HO-1 expression is impaired in adipocytes
deficient in PGC-1a
The expression of PGC-1a protein in the PGC-1a KD
cells was 30%–35% of PGC-1a protein levels in WT cells
(Fig. 3A, B). Since EET increased PGC-1a levels (Fig. 2)
and EET is known to increase HO-1 protein expression, we
measured HO-1 in WT, Mock, and PGC-1a KD adipocyte
cells treated with EET-A. In WT and Mock adipocyte cells,
EET increased HO-1 levels (Fig. 3C). However, in PGC-1a
KD adipocyte cells, EET failed to increase the expression of
HO-1, suggesting that PGC-1a is necessary for HO-1 ex-
pression (Fig. 3D).
PGC-1a knockdown decreases
mitochondrial viability
Mitochondrial superoxide levels were elevated in PGC-
1a-deficient cells compared with WT cells (Fig. 4A, B), and
EET-A significantly reduced mitochondrial superoxide
levels in WT cells (P < 0.05) (Fig. 4C). UCP-1 protein levels
were lower in PGC-1a-deficient cells compared with those
in WT cells (Fig. 4D). Treatment with EET-A increased
UCP-1 protein levels in WT cells (P< 0.05) but did not
affect the UCP-1 levels in PGC-1a-deficient cells (Fig. 4D).
Adipocyte cell heme levels were higher in the WT control
compared with the EET-A-treated cells (Fig. 4E).
PGC-1a knockdown prevents EET-mediated
HO-1 induction
To examine if EET induction of HO-1 is mediated
through PGC-1a, preadipocytes were transfected with PGC-
1a shRNA. As seen in Fig. 5A and B, the EET-mediated
increase in HO-1 protein was abolished in PGC-1a-deficient
cells, suggesting that EET-A increases HO-1 through the
direct effect of PGC-1a. As shown in Fig. 5C and D, the
levels of manganese superoxide dismutase (MnSOD) are
threefold lower in PGC-1a-deficient adipocyte cells com-
pared with WT cells. Moreover, cells treated with EET-A
displayed an increased level of MnSOD protein in both WT
cells and PGC-1a-deficient cells (Fig. 5C, D).
Effect of EET-A on b-catenin and Wnt10b
We examined whether expression of b-catenin and
wingless-type MMTV integration site family, member 10b
(Wnt10b) is dependent on the levels of PGC-1 expression by
FIG. 2. Inflammatory and adipo-
genesismarkers. Theproinflammatory
cytokines IL-1a (A) and IL-6 (B)
were measured by ELISA in the
conditioned medium of treated and
nontreated adipocytes at 7 days of
differentiation and treated with
EET-A and SnMP. (C) Adiponectin
(HMW) levels in differentiated 3T3
cells treated with EET-A (1mM).
Adiponectin levels secreted into the
conditionedmediumweremeasured
using ELISA, n= 3–5 in each group,
*P<0.05, #P<0.05, and **P<
0.05 versus EET-A (1mM). EET-A,
epoxyeicosatrienoic acid; IL-6, inter-
leukin 6.
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EET. Treatment of adipocyte cells with EET-A significantly
(*P < 0.05) increased both b-catenin and Wnt10b mRNA
expression levels compared with control (Fig. 6A, B), sug-
gesting the involvement of HO-1-PGC-1 signaling in regu-
lation of stage of differentiations of mouse adipocytes.
Effect of EET-A on MEST mRNA and protein levels
To further characterize the effect of EET-A on adipocytes
during maturation, we examined the levels of mesoderm-
specific transcript/paternally expressed gene 1 protein
(MEST/Peg1). As seen in Fig. 7A and B, treatment of ad-
ipocyte cells with EET-A (10mM) during differentiation for
7–8 days reduced MEST mRNA and protein levels com-
pared with vehicle control cells.
Discussion
This is the first study to demonstrate that EET, a lipid
mediator, is situated upstream of the PGC-1a signaling
cascade and plays a critical role in the regulation of adi-
pocyte differentiation. Furthermore, this process involves an
increase in HO-1 expression and inhibition of the progres-
sion toward terminal adipocyte differentiation. These novel
findings highlighting EET–PGC-1a interplay suggest that
this plays a significant role in adipocyte proliferation, clonal
expansion, growth arrest, and differentiation. The tran-
scriptional coactivator PGC-1a, first identified as a regulator
of PPAR-g in brown adipose tissue rich in the mitochondria,
has a special role in thermogenesis [31]. PGC-1a is highly
expressed in tissues with a high energy demand, such as the
heart, skeletal muscle, and brown adipose tissue, where it
plays a critical role in maintaining mitochondrial biogenesis
and function and as well as cellular energy metabolism
[11,41]. In PGC-1a-deficient cells, HO-1 levels are reduced
compared with wild-type cells or Mock cells (Fig. 3C, D).
This novel finding adds support to our report that PGC-1a is
essential for the EET-mediated increase in HO-1 expression
and a critical role for PGC-1a in reducing adipogenesis by
controlling heme levels. These results identify PGC-1a as a
key component of the regulatory pathway involved in the
control of mitochondria-derived ROS and adiponectin re-
lease. PGC-1a expression is increased in response to phys-
iological stimuli that demand increased mitochondrial
energy production, such as exercise and fasting [42–45], and
may play an important role in the development of antiobe-
sity therapies.
Exogenous EET reduced clonal expansion of adipocytes,
thereby favoring healthy small adipocytes, as opposed to hy-
pertrophic lipid accumulation. Protection against adipose tis-
sue dysfunction, including preservation of anti-inflammatory
adipokines such as adiponectin, is related to an adipocyte of
smaller size [7,10,23,46]. The beneficial effect of EET-A was
blocked by SnMP, indicating that EET is working through the
HO system,which controls the cellular levels of heme, leading
FIG. 3. (A and B) PGC-1a protein is
reduced in the 3T3-L1 preadipocyte.
Data are shown as mean band density
normalized to b-actin (mean – SE;
n = 3; *P < 0.05 compared to WT). (C
and D) The effect of EET on HO-1
expression in WT and PGC-1a KD
adipocyte cells was compared. Fully
differentiated cells were treated with
1 mM EET-A for 2 days in WT, Mock,
and PGC-1a KD cells. Cells were
lysed, and protein expression was de-
termined (*P < 0.01 compared to WT,
n = 3). EET-A, epoxyeicosatrienoic
acid; PGC-1a, proliferation-activated
receptor g coactivator a.
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FIG. 4. (A) Representative plot
showing flow cytometry analysis of
mitochondrial superoxide levels in WT
(left panel) and PGC-1a-deficient (right
panel) undifferentiated adipocytes and
(B) statistical analysis of the integrated
MitoSox fluorescence intensity, n = 3,
*P < 0.05 compared to WT. (C) Mi-
tochondrial superoxide levels in WT
adipocytes as measured by MitoSox
incorporation and analysis of HPLC,
n = 3, *P < 0.05 versus control. (D)
Representative western blot showing
UCP-1 protein levels in WT and PGC-
1a-deficient cells (top) and the densi-
tometry analysis (bottom), n = 3, *P<
0.05 compared to control. (E) Mea-
surement of adipocyte heme levels,
n = 3, *P < 0.05 compared to control.
PGC-1a, proliferation-activated re-
ceptor g coactivator a; UCP-1, un-
coupling protein 1.
FIG. 5. Western blot analysis for the expression of the HO-1 protein in WT and PGC-1a-deficient cells with and without
EET-A (10mM) treatment. Representative blots of HO-1 and b-actin (A) and densitometry analysis of HO-1 protein levels,
normalized to b-actin in untreated (control) and cells treated for 7 days with EET-A, added every other day (B). Western
blot analysis of the expression of the antioxidant protein MnSOD in differentiated adipocytes. WT- and PGC-1a-silenced
cells with and without EET-A (10mM) treatment. Representative blots of MnSOD and b-actin (C) and densitometry
analysis of MnSOD protein levels, normalized to b-actin in untreated (control) and cells treated for 7 days or 16 h after EET-
A supplementation for protein measurement and mRNA, respectively, following treatment with EET-A (D). n = 3, *P< 0.05
compared to WT; **P< 0.01 compared to WT EET-A treated. EET-A, epoxyeicosatrienoic acid; HO-1, heme oxygenase-1;
MnSOD, manganese superoxide dismutase; PGC-1a, proliferation-activated receptor g coactivator a.
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to terminal adipocyte stem cell differentiation and enlarge-
ment. It is clear that PGC-1a regulates heme levels by two
mechanisms: by increased 5¢-aminolevulinate synthase
(ALAS, the rate-limiting enzyme of heme biosynthesis) and
heme levels needed for full differentiation; simultaneously,
PGC-1a increases HO-1 as a result of EET treatment that
reduces heme levels and prevents terminal adipocyte differ-
entiation. SnMP increases levels of cellular heme by inhibiting
heme oxygenase, the rate-limiting enzyme in heme degrada-
tion [47].We report here that EET increases PGC-1a, an effect
not blocked by SnMP. This confirms previous studies showing
that PGC-1a is particularly sensitive to intracellular heme
levels, particularly via Rev-Erba regulation [12], and plays a
significant role in the increase in the levels of heme by upre-
gulation of ALAS [48]. However, EET-mediated increase in
PGC-1a leading to increased levels of HO-1 also reduced
heme to control adipocyte cells during terminal differentia-
tion. Interestingly, SnMP increases cellular heme levels, while
EET increases HO-1 via PGC-1a. Therefore, the net effect of
SnMP treatment did not negatively impact PGC-1amRNA or
protein levelswhen added to cells togetherwith EET.This is in
all probability due to the fact that EET decreases heme and
SnMP increases heme, leaving PGC-1a levels unchanged.We
speculate that the EET-mediated increase in PGC-1a affects
adipocyte expansion and full differentiation by several
mechanisms: (1) by acting upstream of PGC-1a and by de-
creasing heme levels via induction of HO-1, (2) by increasing
mitochondrialMnSODandUCP-1, and (3) through a decrease
in MEST/PEG1, necessary for terminal differentiation and
adipocyte enlargement [7,13,18,23,28,49–52].
FIG. 6. Effect ofEET-A (10mM)onexpression ofb-catenin
and Wnt10b, mRNA, and/or protein levels. (A) b-catenin
mRNA levels. (B) Wnt10b mRNA levels, n= 3, *P< 0.05
versus control. EET-A, epoxyeicosatrienoic acid; Wnt10b,
wingless-type MMTV integration site family, member 10b.
FIG. 7. Effect of EET-A (10mM) onMESTmRNA (A) and
protein (B) levels after 7–8 days of differentiation. n= 3,
*P< 0.05versus control.MEST,mesoderm-specific transcript.
FIG. 8. Schematic presentation of the possiblemechanism by
which EET-PGC-1amodulates pluripotent hematopoietic stem
cell precursors that give rise to a mesenchymal precursor cell
with the potential to differentiate along mesodermal lineages
intomyoblast, including adipocytes.WhenMSC is placed under
appropriate adipogenic conditions, MSC begins to exhibit spe-
cific gene expression in preadipocytes that undergo prolifera-
tion, clonal expansion, and growth arrest. EET synthesis by
Cyp2c44 increases PGC-1a levels and translocation to the nu-
cleus. In the nucleus together with PGC-1a induced the ex-
pression of HO-1 and UCP-1. HO-1 reduces mitochondrial
superoxide [55] and increases Cyp2c44 levels and activity. Ar-
rows indicate that PGC-1a-HO-1 effect is present at 2–3 steps in
the differentiation of MSC to terminally differentiated adipo-
cytes. During this process, PGC-1a increases HO-1 expression,
which is associated with a decrease in mitochondria-derived
ROS (MitoSox). HO-1 gene activation resulted in reprogram-
ming the adipocyte phenotype to express a new healthy phe-
notype, as evidenced by the expression of fatty acid oxidation
enzymes, Wnt10b signaling, and release of adiponectin, while
PGC-1a increases the expression of thermogenic genes, in-
cluding UCP-1, decreases MEST, and prevents cells entering
into proinflammatory cytokines, increasing detrimental sys-
temic effects on other organs. EET, epoxyeicosatrienoic acid;
HO-1, heme oxygenase-1;MSC,mesenchymal stem cell; PGC-
1a, proliferation-activated receptor g coactivator a; ROS, re-
active oxygen species; UCP-1, uncoupling protein 1; Mfn1,
Mfn2, mitochondrial fusion proteins-1 and 2.
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HO-1 has multiple cellular effects, including regulating
bioavailability of heme and heme-containing denatured
proteins [53], generation of bioactive metabolites—carbon
monoxide (CO) and biliverdin (BV), preventing the cellular
buildup of free (nonprotein bound) heme, and preventing
free radical and mitochondrial dysfunction [53,54]. HO-1
plays a role in mitochondrial biogenesis and function and
cytochrome oxidase [55,56]. The effect of PGC-1a on mi-
tochondrial function and adipogenesis is exemplified by the
EET-A-mediated increase in Cyp2c44, leading to a new
transcriptional role during adipogenesis, for example, by
activation of PGC-1a expression and reduction in mito-
chondrial ROS levels (Fig. 4). These results provide a new
pathway comprising EET, PGC-1a, and HO-1 that forms a
positive feedback loop that stimulates mitochondrial func-
tion. Thus, EET, PGC-1a, and HO-1 appear to form a
module that serves as a molecular ‘‘switch’’ to genetically
reprogram the adipocyte phenotype to express lower levels
of MEST (Fig. 7A, B) and prevent hypoadiponectinemia
[7,18] through upregulation of PGC-1a and an increase in
mitochondrial function and a decrease in MitoSox.
EET is the first lipidmediator derived from lipidmetabolism
via the CYP system to regulate PGC-1a. A dearth of EET is
considered to be the leading promoter of adipocyte hypertro-
phy and dysfunction (large adipocyte). Cells treated with EET
are associated with upregulation of PGC-1a-HO-1, suggesting
that EETs regulate adipocyte progression toward differentia-
tion and adipogenesis through the activation of PGC-1a sig-
naling. Moreover, the protein level of the adipogenic MEST
increased with differentiation (data not shown). Importantly,
the MEST mRNA and protein levels were reduced by treat-
ment of cells with EET-A during differentiation (Fig. 7).
We show here a direct link between EET-mediated activa-
tion of PGC-1a and reduction in mitochondrial ROS produc-
tion results in an increase in the number of small adipocytes.
This novel finding demonstrates that EET is associated with
epigenetic changes, that is, increases in PGC-1a, HO-1, and
mitochondrial function not seen in terminally differentiated
adipocytes. The EET-mediated increases in PGC-1a, includ-
ing an increase in adiponectin expression and secretion and
reduced secretion of proinflammatory cytokines resulting in a
decrease in the number of the inflamed adipocyte phenotypes,
appear to be dependent on intracellular heme levels as heme is
essential for full differentiation of adipocyte [9,57,58]. These
results are summarized in Fig. 8. During adipogenesis, MSCs
or preadipocytes differentiate into lipid-laden and insulin-
sensitive adipocytes [20]. The acquisition of adipocyte phe-
notype anddevelopment of adipocyte function is characterized
by chronological changes in the expression of multiple genes.
Effect of drugs on programmed adipocyte cell differentiation
may influence adipocytes to express adipogenic markers for
maturation and terminal differentiation or downregulate such
genes in favor of an increase in adiponectin andmitochondrial
function. Adipose tissue and adipocyte cells play an important
role in insulin resistance through the production and secre-
tion of a variety of proteins, including tumor necrosis factor
(TNF)-a, IL-6, leptin, and adiponectin [59–62]. In contrast,
terminal differentiation is associated with adipocyte enlarge-
ment and the expression of several markers, including Peg1/
MEST [7,18,50], and proinflammatory cytokines and sup-
pression of adiponectin synthesis [18,63]. This process is
highly regulated by the appearance of early, intermediate, and
late mRNA/protein markers and triglyceride accumulation
(Fig. 8). This suggests that EET rescues mitochondrial func-
tion by activation of PGC-1a and that interplay between EET
and PGC-1a is inexorably linked in the regulation of HO-1,
heme, and stage of adipocyte growth by modulating the level
of gene expression that leads to adipocyte maturation and
terminal differentiation.
Acknowledgments
This work was supported by the National Institutes of
Health grants HL55601 and HL34300, the Brickstreet Foun-
dation and the Huntington Foundation (NGA) and gifts from
the Ablon, Lang and Renfield Foundations to The Rockefeller
University (AK). We thank Jennifer Brown for her outstand-
ing editorial assistance in the preparation of the article.
Author Disclosure Statement
All authors had full access to the data and take respon-
sibility for its integrity. All authors have read and agreed
with the article as written. There are no conflicts of interest
among the authors.
References
1. Zeldin DC. (2001). Epoxygenase pathways of arachidonic
acid metabolism. J Biol Chem 276:36059–36062.
2. Capdevila JH, JR Falck, and RC Harris. (2000). Cyto-
chrome P450 and arachidonic acid bioactivation. Molecular
and functional properties of the arachidonate mono-
oxygenase. J Lipid Res 41:163–181.
3. Node K, Y Huo, X Ruan, B Yang, M Spiecker, K Ley, DC
Zeldin, and JK Liao. (1999). Anti-inflammatory properties
of cytochrome P450 epoxygenase-derived eicosanoids.
Science 285:1276–1279.
4. Spiecker M and JK Liao. (2005). Vascular protective ef-
fects of cytochrome p450 epoxygenase-derived eicosa-
noids. Arch Biochem Biophys 433:413–420.
5. Vanella L, DH Kim, D Asprinio, SJ Peterson, I Barbagallo,
A Vanella, D Goldstein, S Ikehara, A Kappas, and NG
Abraham. (2010). HO-1 expression increases mesenchymal
stem cell-derived osteoblasts but decreases adipocyte line-
age. Bone 46:236–243.
6. Burgess AP, L Vanella, L Bellner, K Gotlinger, JR Falck,
NG Abraham, ML Schwartzman, and A Kappas. (2012).
Heme oxygenase (HO-1) rescue of adipocyte dysfunction
in HO-2 deficient mice via recruitment of epoxyeicosa-
trienoic acids (EETs) and adiponectin. Cell Physiol Bio-
chem 29:99–110.
7. Kim DH, L Vanella, K Inoue, A Burgess, K Gotlinger, VL
Manthati, SR Koduru, DC Zeldin, JR Falck, ML Schwartz-
man, and NG Abraham. (2010). Epoxyeicosatrienoic acid
agonist regulates human mesenchymal stem cell-derived
adipocytes through activation of HO-1-pAKT signaling
and a decrease in PPARgamma. Stem Cells Dev 19:1863–
1873.
8. Chen JJ and IM London. (1981). Hemin enhances the differ-
entiation of mouse 3T3 cells to adipocytes. Cell 26:117–
122.
9. Kumar N, LA Solt, Y Wang, PM Rogers, G Bhattacharyya,
TMKamenecka, KR Stayrook, C Crumbley, ZE Floyd, et al.
(2010). Regulation of adipogenesis by natural and synthetic
REV-ERB ligands. Endocrinology 151:3015–3025.
1092 WALDMAN ET AL.
10. Abraham NG, JM Junge, and GS Drummond. (2016).
Translational significance of heme oxygenase in obesity
and metabolic syndrome. Trends Pharmacol Sci 37:17–36.
11. Wu Z, P Puigserver, U Andersson, C Zhang, G Adelmant,
V Mootha, A Troy, S Cinti, B Lowell, RC Scarpulla, and
BM Spiegelman. (1999). Mechanisms controlling mito-
chondrial biogenesis and respiration through the thermo-
genic coactivator PGC-1. Cell 98:115–124.
12. WuN, L Yin, EAHanniman, S Joshi, andMALazar. (2009).
Negative feedback maintenance of heme homeostasis by its
receptor, Rev-erbalpha. Genes Dev 23:2201–2209.
13. Burgess A, L Vanella, L Bellner, ML Schwartzman, and
NG Abraham. (2012). Epoxyeicosatrienoic acids and heme
oxygenase-1 interaction attenuates diabetes and metabolic
syndrome complications. Prostaglandins Other LipidMediat
97:1–16.
14. Li P, JL Lahvic, V Binder, EK Pugach, EB Riley, OJ Tam-
plin, D Panigrahy, TV Bowman, FG Barrett, et al. (2015).
Epoxyeicosatrienoic acids enhance embryonic haematopoi-
esis and adult marrow engraftment. Nature 523:468–471.
15. Lavrovsky Y, ML Schwartzman, RD Levere, A Kappas,
and NG Abraham. (1994). Identification of binding sites for
transcription factors NF-kappa B and AP-2 in the promoter
region of the human heme oxygenase 1 gene. Proc Natl
Acad Sci U S A 91:5987–5991.
16. Sodhi K, N Puri, K Inoue, JR Falck, ML Schwartzman, and
NG Abraham. (2012). EET agonist prevents adiposity and
vascular dysfunction in rats fed a high fat diet via a de-
crease in Bach 1 and an increase in HO-1 levels. Pros-
taglandins Other Lipid Mediat 98:133–142.
17. Zha W, ML Edin, KC Vendrov, RN Schuck, FB Lih, JL Jat,
JA Bradbury, LM Degraff, K Hua, et al. (2014). Functional
characterization of cytochrome P450-derived epoxyeicosa-
trienoic acids in adipogenesis and obesity. J Lipid Res 55:
2124–2136.
18. Vanella L, K Sodhi, DH Kim, N Puri, M Maheshwari, TD
Hinds, Jr., L Bellner, D Goldstein, SJ Peterson, JI Shapiro,
and NG Abraham. (2013). Increased heme-oxygenase 1
expression decreases adipocyte differentiation and lipid
accumulation in mesenchymal stem cells via upregulation
of the canonical Wnt signaling cascade. Stem Cell Res Ther
4:28.
19. Vazquez-Vela ME, N Torres, and AR Tovar. (2008). White
adipose tissue as endocrine organ and its role in obesity.
Arch Med Res 39:715–728.
20. Lefterova MI and MA Lazar. (2009). New developments in
adipogenesis. Trends Endocrinol Metab 20:107–114.
21. Rosen ED, CJ Walkey, P Puigserver, and BM Spiegelman.
(2000).Transcriptional regulationof adipogenesis.GenesDev
14:1293–1307.
22. Gregoire FM, CM Smas, and HS Sul. (1998). Understanding
adipocyte differentiation. Physiol Rev 78:783–809.
23. Burgess A, M Li, L Vanella, DH Kim, R Rezzani, L
Rodella, K Sodhi, M Canestraro, P Martasek, SJ et al.
(2010). Adipocyte heme oxygenase-1 induction attenuates
metabolic syndrome in both male and female obese mice.
Hypertension 56:1124–1130.
24. Ndisang JF. (2010). Role of heme oxygenase in inflam-
mation, insulin-signalling, diabetes and obesity. Mediators
Inflamm 2010:359732.
25. Peterson SJ, G Drummond, DH Kim, M Li, AL Kruger, S
Ikehara, and NG Abraham. (2008). L-4F treatment reduces
adiposity, increases adiponectin levels, and improves in-
sulin sensitivity in obese mice. J Lipid Res 49:1658–1669.
26. Nicolai A, M Li, DH Kim, SJ Peterson, L Vanella, V Po-
sitano, A Gastaldelli, R Rezzani, LF Rodella, et al. (2009).
Heme oxygenase-1 induction remodels adipose tissue and
improves insulin sensitivity in obesity-induced diabetic
rats. Hypertension 53:508–515.
27. Zhang S, G Chen, N Li, M Dai, C Chen, P Wang, H Tang,
SL Hoopes, DC Zeldin, DW Wang, and X Xu. (2015).
CYP2J2 overexpression ameliorates hyperlipidemia via
increased fatty acid oxidation mediated by the AMPK
pathway. Obesity (Silver Spring) 23:1401–1413.
28. Abraham NG, K Sodhi, AM Silvis, L Vanella, G Favero, R
Rezzani, C Lee, DC Zeldin, and Schwartzman ML. (2014).
CYP2J2 targeting to endothelial cells attenuates adiposity and
vascular dysfunction in mice fed a high-fat diet by repro-
gramming adipocyte phenotype.Hypertension 64:1352–1361.
29. Campbell WB. (2000). New role for epoxyeicosatrienoic
acids as anti-inflammatory mediators. Trends Pharmacol Sci
21:125–127.
30. Omata K, K Abe, HL Sheu, K Yoshida, E Tsutsumi, K
Yoshinaga, NG Abraham, and M Laniado-Schwartzman.
(1992). Roles of renal cytochrome P450-dependent arachi-
donic acid metabolites in hypertension. Tohoku J Exp Med
166:93–106.
31. Puigserver P, Z Wu, CW Park, R Graves, M Wright, and
BM Spiegelman. (1998). A cold-inducible coactivator of
nuclear receptors linked to adaptive thermogenesis. Cell 92:
829–839.
32. Bostrom P, J Wu, MP Jedrychowski, A Korde, L Ye, JC Lo,
KA Rasbach, EA Bostrom, JH Choi, et al. (2012). A PGC1-
alpha-dependent myokine that drives brown-fat-like devel-
opment ofwhite fat and thermogenesis. Nature 481:463–468.
33. Puigserver P and BM Spiegelman. (2003). Peroxisome
proliferator-activated receptor-gamma coactivator 1 alpha
(PGC-1 alpha): transcriptional coactivator and metabolic
regulator. Endocr Rev 24:78–90.
34. Wenz T, SG Rossi, RL Rotundo, BM Spiegelman, and CT
Moraes. (2009). Increased muscle PGC-1alpha expression
protects from sarcopenia and metabolic disease during ag-
ing. Proc Natl Acad Sci U S A 106:20405–20410.
35. Kleiner S, RJ Mepani, D Laznik, L Ye, MJ Jurczak, FR
Jornayvaz, JL Estall, BD Chatterjee, GI Shulman, and BM
Spiegelman. (2012). Development of insulin resistance in
mice lacking PGC-1alpha in adipose tissues. Proc Natl
Acad Sci U S A 109:9635–9640.
36. Li R, N Jen, F Yu, and TK Hsiai. (2011). Assessing mi-
tochondrial redox status by flow cytometric methods: vas-
cular response to fluid shear stress. Curr Protoc Cytom
Chapter 9:Unit 9.37.
37. Infantino V, V Iacobazzi, A Menga, ML Avantaggiati, and
F Palmieri. (2014). A key role of the mitochondrial citrate
carrier (SLC25A1) in TNFalpha- and IFNgamma-triggered
inflammation. Biochim Biophys Acta 1839:1217–1225.
38. Alhawaj R,DPatel,MRKelly, DSun, andMSWolin. (2015).
Heme biosynthesis modulation via delta-aminolevulinic acid
administration attenuates chronic hypoxia-induced pulmo-
nary hypertension. Am J Physiol Lung Cell Mol Physiol
308:L719–L728.
39. Sambuceti G, SMorbelli, L Vanella, C Kusmic, CMarini, M
Massollo, C Augeri, M Corselli, C Ghersi, et al. (2009).
Diabetes impairs the vascular recruitment of normal stem
cells by oxidant damage; reversed by increases in pAMPK,
heme oxygenase-1 and adiponectin. Stem Cells 27:399–407.
40. Pfaffl MW. (2001). A new mathematical model for relative
quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
EET UPSTREAM OF PGC-1a REGULATES ADIPOCYTE DEVELOPMENT 1093
41. St-Pierre J, J Lin, S Krauss, PT Tarr, R Yang, CB Newgard,
and BM Spiegelman. (2003). Bioenergetic analysis of
peroxisome proliferator-activated receptor gamma coacti-
vators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in
muscle cells. J Biol Chem 278:26597–26603.
42. Baar K, AR Wende, TE Jones, M Marison, LA Nolte, M
Chen, DP Kelly, and JO Holloszy. (2002). Adaptations of
skeletal muscle to exercise: rapid increase in the tran-
scriptional coactivator PGC-1. FASEB J 16:1879–1886.
43. Terada S and I Tabata. (2004). Effects of acute bouts of
running and swimming exercise on PGC-1alpha protein
expression in rat epitrochlearis and soleus muscle. Am J
Physiol Endocrinol Metab 286:E208-E216.
44. H Pilegaard, B Saltin, and PD Neufer. (2003). Exercise in-
duces transient transcriptional activation of the PGC-1alpha
gene in human skeletal muscle. J Physiol 546:851–858.
45. Rhee J, Y Inoue, JC Yoon, P Puigserver, M Fan, FJ Gonzalez,
and BM Spiegelman. (2003). Regulation of hepatic fasting
response by PPARgamma coactivator-1alpha (PGC-1): re-
quirement for hepatocyte nuclear factor 4alpha in gluconeo-
genesis. Proc Natl Acad Sci U S A 100:4012–4017.
46. Skurk T, C Alberti-Huber, C Herder, and H Hauner. (2007).
Relationship between adipocyte size and adipokine ex-
pression and secretion. J Clin Endocrinol Metab 92:1023–
1033.
47. Drummond GS and A Kappas. (1981). Prevention of neo-
natal hyperbilirubinemia by tin protoporphyrin IX, a potent
competitive inhibitor of heme oxidation. Proc Natl Acad
Sci U S A 78:6466–6470.
48. Handschin C, J Lin, J Rhee, AK Peyer, S Chin, PH Wu, UA
Meyer, and BM Spiegelman. (2005). Nutritional regulation
of hepatic heme biosynthesis and porphyria through PGC-
1alpha. Cell 122:505–515.
49. Peterson SJ, DH Kim, M Li, V Positano, L Vanella, LF
Rodella, F Piccolomini, N Puri, A Gastaldelli, C Kusmic,
L’Abbate A, and NG Abraham. (2009). The L-4F mimetic
peptide prevents insulin resistance through increased levels
of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res
50:1293–1304.
50. Takahashi M, Y Kamei, and O Ezaki. (2005). Mest/Peg1
imprinted gene enlarges adipocytes and is a marker of adi-
pocyte size.AmJPhysiol EndocrinolMetab 288:E117–E124.
51. Vanella L, Li M, D Kim, G Malfa, L Bellner, T Kawakami,
and Abraham NG. (2012). ApoA1: mimetic peptide reverses
adipocyte dysfunction in vivo and in vitro via an increase in
hemeoxygenase (HO-1) andWnt10b.CellCycle 11:706–714.
52. Vanella L, DH Kim, K Sodhi, I Barbagallo, AP Burgess, JR
Falck,MLSchwartzman, andNGAbraham. (2011). Crosstalk
between EET andHO-1 downregulates Bach1 and adipogenic
marker expression in mesenchymal stem cell derived adipo-
cytes. Prostaglandins Other Lipid Mediat 96:54–62.
53. Abraham NG and A Kappas. (2008). Pharmacological and
clinical aspects of heme oxygenase. Pharmacol Rev 60:
79–127.
54. Balla J, HS Jacob, G Balla, K Nath, JW Eaton, and GM
Vercellotti. (1993). Endothelial-cell heme uptake from
heme proteins: induction of sensitization and desensitiza-
tion to oxidant damage. Proc Natl Acad Sci U S A 90:
9285–9289.
55. Di Noia MA, DS Van, F Palmieri, LM Yang, S Quan, AI
Goodman, and NG Abraham. (2006). Heme oxygenase-1
enhances renal mitochondrial transport carriers and cyto-
chrome C oxidase activity in experimental diabetes. J Biol
Chem 281:15687–15693.
56. Piantadosi CA, MS Carraway, A Babiker, and HB Suliman.
(2008). Heme oxygenase-1 regulates cardiac mitochondrial
biogenesis via Nrf2-mediated transcriptional control of
nuclear respiratory factor-1. Circ Res 103:1232–1240.
57. Chen JK, JR Falck, KM Reddy, J Capdevila, and RC
Harris. (1998). Epoxyeicosatrienoic acids and their sulfo-
nimide derivatives stimulate tyrosine phosphorylation and
induce mitogenesis in renal epithelial cells. J Biol Chem
273:29254–29261.
58. Puri N, K Sodhi, M Haarstad, DH Kim, S Bohinc, E Foglio,
G Favero, and NG Abraham. (2012). Heme induced oxi-
dative stress attenuates sirtuin1 and enhances adipogenesis
in mesenchymal stem cells and mouse pre-adipocytes. J
Cell Biochem 113:1926–1935.
59. Kershaw EE and JS Flier. (2004). Adipose tissue as an
endocrine organ. J Clin Endocrinol Metab 89:2548–2556.
60. Berg AH and PE Scherer. (2005). Adipose tissue, inflam-
mation, and cardiovascular disease. Circ Res 96:939–949.
61. Fain JN, Madan AK, Hiler ML, P Cheema, and SW Ba-
houth. (2004). Comparison of the release of adipokines by
adipose tissue, adipose tissue matrix, and adipocytes from
visceral and subcutaneous abdominal adipose tissues of
obese humans. Endocrinology 145:2273–2282.
62. Kim JY, van de WE, M Laplante, A Azzara, ME Trujillo,
SM Hofmann, T Schraw, JL Durand, H Li, et al. (2007).
Obesity-associated improvements in metabolic profile through
expansion of adipose tissue. J Clin Invest 117:2621–2637.
63. Kim DH, N Puri, K Sodhi, JR Falck, NG Abraham, J
Shapiro, and ML Schwartzman. (2013). Cyclooxygenase-2
dependent metabolism of 20-HETE increases adiposity and
adipocyte enlargement in mesenchymal stem cell-derived
adipocytes. J Lipid Res 54:786–793.
Address correspondence to:
Dr. Nader G. Abraham
Departments of Medicine and Pharmacology
New York Medical College
15 Dana Road
Basic Science Building, Room 509
Valhalla, NY 10595-1554
E-mail: nader_abraham@nymc.edu
Received for publication March 18, 2016
Accepted after revision May 20, 2016
Prepublished on Liebert Instant Online May 25, 2016
1094 WALDMAN ET AL.
This article has been cited by:
1. Francesca Schinzari, Manfredi Tesauro, Carmine Cardillo. 2017. Endothelial and Perivascular Adipose Tissue Abnormalities in
Obesity-Related Vascular Dysfunction. Journal of Cardiovascular Pharmacology 69:6, 360-368. [CrossRef]
2. Eun-Jeong Koh, Kui-Jin Kim, Young-Jin Seo, Jia Choi, Boo-Yong Lee. 2017. Modulation of HO-1 by Ferulic Acid Attenuates
Adipocyte Differentiation in 3T3-L1 Cells. Molecules 22:5, 745. [CrossRef]
3. Dariusz Galkowski, Mariusz Z. Ratajczak, Janusz Kocki, Zbigniew Darzynkiewicz. 2017. Of Cytometry, Stem Cells and Fountain
of Youth. Stem Cell Reviews and Reports 166. . [CrossRef]
4. Mikhail Romashko, Joseph Schragenheim, Nader G. Abraham, John A. McClung. 2016. Epoxyeicosatrienoic Acid as Therapy
for Diabetic and Ischemic Cardiomyopathy. Trends in Pharmacological Sciences 37:11, 945-962. [CrossRef]
5. Shailendra P. Singh, Joseph Schragenheim, Jian Cao, John R. Falck, Nader G. Abraham, Lars Bellner. 2016. PGC-1 alpha
regulates HO-1 expression, mitochondrial dynamics and biogenesis: Role of epoxyeicosatrienoic acid. Prostaglandins & Other Lipid
Mediators 125, 8-18. [CrossRef]
6. Shailendra P. Singh, Lars Bellner, Luca Vanella, Jian Cao, John R. Falck, Attallah Kappas, Nader G. Abraham. 2016.
Downregulation of PGC-1 α Prevents the Beneficial Effect of EET-Heme Oxygenase-1 on Mitochondrial Integrity and Associated
Metabolic Function in Obese Mice. Journal of Nutrition and Metabolism 2016, 1-15. [CrossRef]
